Inhaltsbereich
| 152 Einträge | 1, 2, 3, 4, 5, 6, 7, 8 › » |
Seite 1 / 8
 Druckansicht
|
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
| Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A |
| The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9 |
| PMID: 29146401 |
| Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker. |
| Leisser A, Pruscha K, Ubl P, Wadsak W, Mayerhöfer M, Mitterhauser M, Hacker M, Kramer G, Shariat S, Karanikas G, Hartenbach M, Haug AR |
| The Prostate. 2015 Aug 18. doi: 10.1002/pros.23061 |
| PMID: 26282590 |
| The germacranolide sesquiterpene lactone neurolenin B of the medicinal plant Neurolaena lobata (L.) R.Br. ex Cass inhibits NPM/ALK-driven cell expansion and NF-κB-driven tumour intravasation. |
| Unger C, Kiss I, Vasas A, Lajter I, Kramer N, Atanasov AG, Nguyen CH, Chatuphonprasert W, Brenner S, Krieger S, McKinnon R, Peschel A, Kain R, Saiko P, Szekeres T, Kenner L, Hassler MR, Diaz R, Frisch R, Dirsch VM, Jäger W, de Martin R, Bochkov VN, Passreiter CM, Peter-Vörösmarty B, Mader RM, Grusch M, Dolznig H, Kopp B, Zupko I, Hohmann J, Krupitza G |
| Phytomedicine : international journal of phytotherapy and phytopharmacology. 2015 Jun 26. pii: S0944-7113(15)00182-8. doi: 10.1016/j.phymed.2015.06.003 |
| PMID: 26220634 |
| STAT3 regulated ARF expression suppresses prostate cancer metastasis. |
| Pencik J, Schlederer M, Gruber W, Unger C, Walker SM, Chalaris A, Marié IJ, Hassler MR, Javaheri T, Aksoy O, Blayney JK, Prutsch N, Skucha A, Herac M, Krämer OH, Mazal P, Grebien F, Egger G, Poli V, Mikulits W, Eferl R, Esterbauer H, Kennedy R, Fend F, Scharpf M, Braun M, Perner S, Levy DE, Malcolm T, Turner SD, Haitel A, Susani M, Moazzami A, Rose-John S, Aberger F, Merkel O, Moriggl R, Culig Z, Dolznig H, Kenner L |
| Nature communications. 2015 Jul 22. pii: ncomms8736. doi: 10.1038/ncomms8736 |
| PMID: 26198641 |
| High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFκB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts. |
| Rudisch A, Dewhurst MR, Horga LG, Kramer N, Harrer N, Dong M, van der Kuip H, Wernitznig A, Bernthaler A, Dolznig H, Sommergruber W |
| PloS one. 2015 Apr 28. doi: 10.1371/journal.pone.0124283. pii: PONE-D-14-36672. pmc: PMC4412534 |
| PMID: 25919140 |
| Modeling human carcinomas: physiologically relevant 3D models to improve anti-cancer drug development. |
| Unger C, Kramer N, Walzl A, Scherzer M, Hengstschläger M, Dolznig H |
| Advanced drug delivery reviews. 2014 Oct 23. pii: S0169-409X(14)00223-3. doi: 10.1016/j.addr.2014.10.015 |
| PMID: 25453261 |
| Lobatin B inhibits NPM/ALK and NF-κB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation. |
| Kiss I, Unger C, Huu CN, Atanasov AG, Kramer N, Chatruphonprasert W, Brenner S, McKinnon R, Peschel A, Vasas A, Lajter I, Kain R, Saiko P, Szekeres T, Kenner L, Hassler MR, Diaz R, Frisch R, Dirsch VM, Jäger W, de Martin R, Bochkov VN, Passreiter CM, Peter-Vörösmarty B, Mader RM, Grusch M, Dolznig H, Kopp B, Zupko I, Hohmann J, Krupitza G |
| Cancer letters. 2014 Nov 15. pii: S0304-3835(14)00675-2. doi: 10.1016/j.canlet.2014.11.019 |
| PMID: 25444930 |
| Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patients. |
| Lucca I, Rouprêt M, Kluth L, Rink M, Tilki D, Fajkovic H, Kassouf W, Hofbauer SL, de Martino M, Karakiewicz PI, Briganti A, Trinh QD, Seitz C, Fritsche HM, Burger M, Lotan Y, Kramer G, Shariat SF, Klatte T |
| BJU international. 2015 Jan 26. doi: 10.1111/bju.12829 |
| PMID: 24905084 |
| Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. |
| Tschirdewahn S, Reis H, Niedworok C, Nyirady P, Szendröi A, Schmid KW, Shariat SF, Kramer G, vom Dorp F, Rübben H, Szarvas T |
| Urologic oncology. 2014 May 9. pii: S1078-1439(14)00035-0. doi: 10.1016/j.urolonc.2014.02.004 |
| PMID: 24814404 |
| Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. |
| Szarvas T, Reis H, Kramer G, Shariat SF, Vom Dorp F, Tschirdewahn S, Schmid KW, Kovalszky I, Rübben H |
| Human pathology. 2013 Dec 18. pii: S0046-8177(13)00530-3. doi: 10.1016/j.humpath.2013.10.036 |
| PMID: 24656090 |
| Prognostic value of tissue and circulating levels of IMP3 in prostate cancer. |
| Szarvas T, Tschirdewahn S, Niedworok C, Kramer G, Sevcenco S, Reis H, Shariat SF, Rübben H, vom Dorp F |
| International journal of cancer. Journal international du cancer. 2014 Mar 4. doi: 10.1002/ijc.28808 |
| PMID: 24615121 |
| EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells. |
| Rommer A, Steinmetz B, Herbst F, Hackl H, Heffeter P, Heilos D, Filipits M, Steinleitner K, Hemmati S, Herbacek I, Schwarzinger I, Hartl K, Rondou P, Glimm H, Karakaya K, Krämer A, Berger W, Wieser R |
| PloS one. 2013 Feb 14. doi: 10.1371/journal.pone.0056308. pii: PONE-D-12-22575. pmc: PMC3572987 |
| PMID: 23457546 |
| The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules. |
| Węsierska-Gądek J, Kramer MP |
| Future medicinal chemistry. 2012 Mar 15. doi: 10.4155/fmc.12.12 |
| PMID: 22416772 |
| The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications. |
| Węsierska-Gądek J, Kramer MP |
| Expert opinion on investigational drugs. 2011 Oct 21. doi: 10.1517/13543784.2011.628985 |
| PMID: 22017180 |
| Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma. |
| Lamm W, Vogl UM, Bojic M, Zielinski C, Klingler C, Kramer G, Schmidinger M |
| Acta oncologica (Stockholm, Sweden). 2011 Jul 8. doi: 10.3109/0284186X.2011.589404 |
| PMID: 21736504 |
| Insertion/deletion polymorphism of angiotensin I-converting enzyme gene is linked with chromophobe renal cell carcinoma. |
| de Martino M, Klatte T, Schatzl G, Waldert M, Remzi M, Haitel A, Kramer G, Marberger M |
| Urology. 2011 Apr 11. pii: S0090-4295(10)02055-8. doi: 10.1016/j.urology.2010.11.033 |
| PMID: 21477733 |
| Combining an FPTase inhibitor with cisplatin facilitates induction of apoptosis in human A549 lung cancer cells. |
| Weber F, Siska P, Kramer M, Zulehner N, Hackl S, Wesierska-Gádek J |
| Journal of experimental therapeutics & oncology. 2011 Jan 31. |
| PMID: 21275266 |
| Hypothyroidism in patients with renal cell carcinoma: blessing or curse? |
| Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G, Zielinski CC |
| Cancer. 2010 Sep 15. doi: 10.1002/cncr.25422 |
| PMID: 20845482 |
| Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinoma. |
| Vogl UM, Bojic M, Lamm W, Frischer JM, Pichelmayer O, Kramer G, Haitel A, Kitz K, Harmankaya K, Zielinski CC, Schmidinger M |
| BMC cancer. 2010 Sep 7. pii: 1471-2407-10-480. doi: 10.1186/1471-2407-10-480. pmc: PMC2942853 |
| PMID: 20819239 |
| Renal cell carcinoma Fuhrman grade and histological subtype correlate with complete polymorphic deletion of glutathione S-transferase M1 gene. |
| De Martino M, Klatte T, Schatzl G, Remzi M, Waldert M, Haitel A, Stancik I, Kramer G, Marberger M |
| The Journal of urology. 2010 Jan 18. pii: S0022-5347(09)02921-8. doi: 10.1016/j.juro.2009.11.032 |
| PMID: 20083259 |
| 152 Einträge | 1, 2, 3, 4, 5, 6, 7, 8 › » |
Seite 1 / 8
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
